Home > Journals > Minerva Respiratory Medicine > Past Issues > Minerva Respiratory Medicine 2023 September;62(3) > Minerva Respiratory Medicine 2023 September;62(3):126-34

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   Free accessfree

Minerva Respiratory Medicine 2023 September;62(3):126-34

DOI: 10.23736/S2784-8477.23.02063-6

Copyright © 2023 EDIZIONI MINERVA MEDICA

language: English

Current treatment of sarcoidosis

Pau MARRADES 1, Juan P. OROZCO 1, Joel FRANCESQUI 1, 2 , Jacobo SELLARES 1

1 Department of Pulmonology, Respiratory Institute, Hospital Clínic de Barcelona, Barcelona, Spain; 2 Department of Pulmonology, Fundació Privada Hospital Asil de Granollers (FPHAG), Granollers, Spain



Sarcoidosis is a systemic granulomatous disease with almost 90% of intrathoracic involvement. Therapeutic management of the disease is challenging as clinical presentation and prognosis are heterogeneous. Self-limited disease is the most common presentation; however, 10-20% of patients may develop progressive disease. Recognition of this phenotype is important as it carries a poor prognosis and a limited response to treatment. The goals of sarcoidosis therapy are to prevent or to minimize organ damage, to relieve symptoms, and to improve the patient’s quality of life. In this review, we summarized the main advances in sarcoidosis pharmacotherapy. Current available therapies for sarcoidosis include glucocorticoids, immunosuppressants, and TNF-alfa antagonists. Other agents (such as rituximab), repository corticotropin and combined antibiotic treatment may have a role in selected cases. Recent evidence shows that antifibrotic agents, such as nintedanib, have a role in fibrotic lung disease, as well as efzofitimob, which has shown promising results in controlling inflammatory lung disease. Although the number of studies of therapies for pulmonary sarcoidosis has increased in recent years, the information available is still limited and there is no consensus on how to monitor the activity of the disease.


KEY WORDS: Sarcoidosis; Glucocorticoids; Immunosuppressive agents; Nintedanib

top of page